Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Holding HALO?
Track your performance easily
HALO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$32.83 - $65.53
Previous Close$59.5
Volume2.61M
Average Volume (3M)1.30M
Market Cap
$7.54B
Enterprise Value$8.51B
Total Cash (Recent Filing)$529.03M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)23.1
Beta1.18
Next Earnings
Nov 04, 2024EPS Estimate
$0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.58
Shares Outstanding126,678,280
10 Day Avg. Volume1,143,372
30 Day Avg. Volume1,304,865
Standard Deviation0.13
R-Squared0.27
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)26.10
Price to Sales (P/S)9.04
Price to Cash Flow (P/CF)35.40
P/FCF Ratio37.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.75
Enterprise Value/Gross Profit13.36
Enterprise Value/Ebitda16.39
Forecast
1Y Price Target
$60.89Price Target Upside2.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Halozyme News
Bulls Say, Bears Say
Bulls Say
Market PotentialENHANZE technology could help capture a large portion of the infusion therapy market and drive its growth.
PartnershipsHALO is in 'broad-based' discussions with pharma and biotech companies for new deals.
Product ApprovalSubcutaneous Ocrevus approved in U.S. for use in two forms of multiple sclerosis.
Bears Say
Commercial RiskRisks include commercial risk with ENHANZE, particularly in the multiple myeloma indication, which is dynamic and rapidly evolving.
CompetitionIf a competitor such as Alteogen or XERS announces major new business for its version of hyaluronidase, it would be a negative for investor perception.
ValuationWith HALO stock blowing past even our updated, higher valuation, the case for further upside relative to other stocks in our coverage is challenging.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $32.83 and its highest was $65.53 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Aug 06, 2024. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.739 by $0.171.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is $0.99.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 126,678,280 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $0.91 in its last earnings report, beating expectations of $0.739. Following the earnings report the stock price went up 4.197%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Fisher Asset Management LLC. It holds Halozyme Therapeutics’s shares valued at 16M.
---
Halozyme Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.89 (2.79% Upside)
$60.89 (2.79% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 93%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 47.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.61%
12-Months-Change
Fundamentals
Return on Equity
153.16%
Trailing 12-Months
Asset Growth
8.78%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
HALO Company Deck
---
HALO Earnings Call
Q2 2024
0:00 / 0:00
---
HALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
HALO Stock 12 Month Forecast
Average Price Target
$60.89
▲(2.79% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Best Analysts Covering HALO
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+37.41%
reiterated a buy rating 5 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +37.41% per trade.
---